GLMD Stock Overview
A biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Galmed Pharmaceuticals Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.43 |
| 52 Week High | US$23.80 |
| 52 Week Low | US$2.56 |
| Beta | 0.67 |
| 1 Month Change | 22.50% |
| 3 Month Change | -13.82% |
| 1 Year Change | -33.51% |
| 3 Year Change | -98.83% |
| 5 Year Change | -99.71% |
| Change since IPO | -99.87% |
Recent News & Updates
Recent updates
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
May 16
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 06Galmed GAAP EPS of -$0.15 beats by $0.09
Aug 04Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky
May 03Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 15Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
Oct 02Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?
May 20Galmed gets greenlight for late-stage Aramchol NASH trial in China
May 03What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?
Feb 04
We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth
Dec 06Galmed EPS misses by $0.02
Nov 12Shareholder Returns
| GLMD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.9% | 0.2% | -0.2% |
| 1Y | -33.5% | -4.7% | 25.8% |
Return vs Industry: GLMD underperformed the US Biotechs industry which returned -4.7% over the past year.
Return vs Market: GLMD underperformed the US Market which returned 25.8% over the past year.
Price Volatility
| GLMD volatility | |
|---|---|
| GLMD Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GLMD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GLMD's weekly volatility has decreased from 44% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 6 | Allen Baharaff | www.galmedpharma.com |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
Galmed Pharmaceuticals Ltd. Fundamentals Summary
| GLMD fundamental statistics | |
|---|---|
| Market cap | US$5.17m |
| Earnings (TTM) | -US$6.32m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs GLMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.32m |
| Earnings | -US$6.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GLMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 21:55 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Galmed Pharmaceuticals Ltd. is covered by 14 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Edward Nash | Canaccord Genuity |
| Elemer Piros | Cantor Fitzgerald & Co. |